The relentless expansion of Pharma’s R&D pipeline was checked somewhat last year, even as the proportion of drugs in active development for cancer reached new heights, and the burgeoning industry in Asia made its presence felt.
The overall pipeline size reached 21,292 drugs in development at the start of 2023, a 5.89% increase from the same...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?